Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BRICANYL vs BREO ELLIPTA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Beta-2 adrenergic receptor agonist; stimulates adenyl cyclase, increasing cyclic AMP, leading to bronchodilation.
Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.
Treatment or prevention of bronchospasm in patients with reversible obstructive airway disease,Acute asthma exacerbation,Off-label: Management of acute hyperkalemia,Off-label: Prevention of preterm labor (terbutaline)
Maintenance treatment of chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema,Maintenance treatment of asthma in patients aged 18 years and older
Subcutaneous: 0.25-0.5 mg every 1-2 hours as needed; Intravenous: 0.25-0.5 mg over 1 minute, may repeat every 1-2 hours; Inhalation (metered-dose inhaler): 2 inhalations (0.4 mg) every 6 hours; Nebulized: 2.5-5 mg every 6-8 hours.
One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.
3-4 hours (terminal); prolonged in renal impairment (up to 8-10 hours) and in elderly patients.
Fluticasone furoate: 24 hours (supports once-daily dosing). Vilanterol: 11 hours (supports once-daily dosing).
Metabolized in the liver via sulfonation (sulfotransferase enzymes) and to a minor extent by catechol-O-methyltransferase (COMT).
Fluticasone furoate: primarily metabolized by CYP3A4; Vilanterol: primarily metabolized by CYP3A4.
Primarily renal (60-70% as unchanged drug and metabolites); fecal elimination accounts for a minor fraction (<5%).
Fluticasone furoate is eliminated primarily via fecal excretion (approximately 101% of an oral dose) due to biliary clearance, with minimal renal excretion (<1%). Vilanterol is eliminated via metabolism and subsequent renal (approximately 70% of an IV dose) and fecal (approximately 30% of an IV dose) excretion.
Approximately 25% bound to albumin.
Fluticasone furoate: >99.8% (primarily albumin). Vilanterol: approximately 94% (albumin and alpha-1-acid glycoprotein).
~0.6 L/kg; indicates distribution into total body water.
Fluticasone furoate: approximately 4.5 L/kg (extensive tissue distribution). Vilanterol: approximately 165 L (large Vd, extensive distribution).
Inhalation: ~10-20% (dependent on device and technique); Oral: ~15-20% (due to extensive first-pass metabolism).
Inhaled: Fluticasone furoate absolute bioavailability approximately 15% (lung deposition). Vilanterol absolute bioavailability approximately 27% (lung deposition). Oral bioavailability is negligible for both (<2% for fluticasone furoate, <5% for vilanterol).
No specific dose adjustment recommended for renal impairment; use with caution in severe renal impairment (e GFR <30 m L/min/1.73 m²) due to potential for increased systemic exposure.
No dosage adjustment required for renal impairment. However, use with caution in severe renal impairment due to potential for increased systemic exposure.
No specific dose adjustment recommended; caution in severe hepatic impairment (Child-Pugh Class C) due to reduced clearance.
Child-Pugh Class A and B: No dosage adjustment recommended. Child-Pugh Class C: Contraindicated.
Subcutaneous: 5-10 mcg/kg every 1-2 hours as needed (max 0.5 mg); Intravenous: 5-10 mcg/kg over 1 minute (max 0.5 mg); Inhalation (MDI): 1-2 inhalations (0.2-0.4 mg) every 4-6 hours; Nebulized: 0.01-0.03 mg/kg (max 1 mg) every 6-8 hours.
Indicated for children aged 5 years and older with asthma. For ages 5-11: one inhalation of 100 mcg/25 mcg once daily. For ages 12 and older: same as adult dosing.
Initiate at lower end of dosing range (e.g., subcutaneous 0.125 mg); monitor for tachycardia, hypertension, and tremor; consider age-related decline in renal and hepatic function.
No dose adjustment required for elderly patients. Use with caution due to increased risk of comorbidities and adverse effects.
Not available
Long-acting beta2-adrenergic agonists (LABAs) increase the risk of asthma-related death. Use only as additional therapy for patients not adequately controlled on a long-term asthma control medication or whose disease severity warrants initiation of both an inhaled corticosteroid and a LABA.
Paradoxical bronchospasm may occur,Cardiovascular effects (e.g., tachycardia, arrhythmias, increased blood pressure) use caution with cardiovascular disorders,Hypokalemia may occur,Hyperglycemia reported,Immediate hypersensitivity reactions
Increased risk of asthma-related death when used as monotherapy for asthma without inhaled corticosteroid,Candida infections of the mouth and pharynx,Pneumonia in patients with COPD,Adrenal insufficiency,Hypercorticism and adrenal suppression,Paradoxical bronchospasm,Hypersensitivity reactions including anaphylaxis,Cardiovascular effects like increased blood pressure and heart rate,Eosinophilic conditions,Reduced bone mineral density,Glaucoma and cataracts
Hypersensitivity to any component,Tachydysrhythmias,Cardiac glycoside toxicity with arrhythmias
Status asthmaticus or acute episodes of COPD requiring intensive therapy,Primary treatment of acute asthma exacerbation,Severe hypersensitivity to milk proteins or any ingredient
No significant food interactions. However, avoid excessive caffeine intake (coffee, tea, cola) as it may exacerbate beta-agonist side effects like palpitations and tremor.
No specific food interactions reported. However, grapefruit juice may increase systemic exposure to fluticasone furoate via CYP3A4 inhibition; although clinical significance is low, avoid excessive grapefruit consumption. No dietary restrictions necessary.
Insufficient human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Risk cannot be excluded; use only if clearly needed. First trimester: limited data suggest no major malformations. Second and third trimesters: may cause fetal tachycardia, hypoglycemia, and transient hypocalcemia. Avoid in preterm labor due to maternal and fetal adverse effects.
Insufficient human data; based on animal studies, corticosteroids (fluticasone furoate) and LABA (vilanterol) show no major teratogenicity but may cause fetal growth restriction at high systemic exposures. Avoid in first trimester unless benefit outweighs risk; use lowest effective dose in later trimesters.
Excreted into breast milk in small amounts; M/P ratio approximately 2.5. No adverse effects reported in infants at therapeutic maternal doses. However, monitor infant for signs of beta-2 adrenergic stimulation (e.g., tachycardia, irritability). Consider risk-benefit.
No data on drug excretion in human milk; M/P ratio unknown. Corticosteroids and LABAs are expected to be present in low concentrations. Caution if breastfeeding, especially in preterm infants. Consider alternative therapies.
No specific dose adjustments recommended for asthma or COPD. However, in preterm labor (off-label), use lowest effective dose and shortest duration due to increased risk of maternal pulmonary edema, cardiac ischemia, and fetal effects. Monitor closely.
No specific dose adjustments required due to pregnancy-induced pharmacokinetic changes, but use lowest effective dose to maintain asthma control due to potential fetal risk.
BRICANYL (terbutaline sulfate) is a beta-2 adrenergic agonist used for bronchodilation in asthma and COPD. It can cause transient hypokalemia, hyperglycemia, and tremor. Use with caution in patients with diabetes, hypertension, or hyperthyroidism. Monitor serum potassium in patients on diuretics or with hypoxia. Not recommended for acute severe asthma as monotherapy; prefer short-acting beta-agonists like albuterol.
Breo Ellipta (fluticasone furoate/vilanterol) is an ICS/LABA combination indicated for maintenance treatment of COPD and asthma. It is not for acute bronchospasm. The ELLIPTA inhaler is a once-daily, dry powder inhaler; each actuation delivers a fixed dose. Rinse mouth with water after use without swallowing to reduce oral candidiasis. Monitor for pneumonia in COPD patients. In asthma, it is not indicated for patients under 18 years; for COPD, use only in patients with a history of exacerbations. Do not discontinue abruptly.
Use exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Shake the inhaler well before each use.,Rinse mouth with water after inhalation to prevent oral thrush.,Seek emergency medical help if breathing problems worsen or if you have chest pain or irregular heartbeat.,Monitor blood sugar if diabetic as this medication may raise blood glucose levels.,Avoid caffeine as it may increase side effects like nervousness and rapid heart rate.
Use exactly as prescribed; it is not a rescue inhaler for sudden breathing problems.,Rinse mouth with water after each dose without swallowing to prevent oral thrush.,Do not stop taking this medication without consulting your doctor; stopping can worsen breathing.,Tell your doctor if you have any signs of infection, pneumonia, or worsening breathing.,Store the inhaler at room temperature away from moisture and heat; keep it closed when not in use.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BRICANYL vs BREO ELLIPTA, answered by our medical review team.
BRICANYL is a Beta-2 Agonist that works by Beta-2 adrenergic receptor agonist; stimulates adenyl cyclase, increasing cyclic AMP, leading to bronchodilation.. BREO ELLIPTA is a Corticosteroid/Beta-2 Agonist Combination that works by Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BRICANYL and BREO ELLIPTA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BRICANYL is: Subcutaneous: 0.25-0.5 mg every 1-2 hours as needed; Intravenous: 0.25-0.5 mg over 1 minute, may repeat every 1-2 hours; Inhalation (metered-dose inhaler): 2 inhalations (0.4 mg) every 6 hours; Nebulized: 2.5-5 mg every 6-8 hours.. The standard adult dose of BREO ELLIPTA is: One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BRICANYL and BREO ELLIPTA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BRICANYL is classified as Category C. Insufficient human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Risk cannot be excluded; use only if clearly needed. First trimester: limit. BREO ELLIPTA is classified as Category C. Insufficient human data; based on animal studies, corticosteroids (fluticasone furoate) and LABA (vilanterol) show no major teratogenicity but may cause fetal growth restriction at. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.